Spyre Therapeutics, Inc. SYRE
Set alert
96.56 USD -2.40 -2.43%
At close · Oct 30
96.45 -0.11 -0.11%
After hours · Oct 30, 4:00 PM ET
94.68 Day range 98.96
21.15 52-week range 110.18
- YTD
- +194.75%
- 1 year
- +298.02%
- Open
- 96.78
- Prev close
- 98.96
- Mkt cap
- 9.02B
- Vol
- 661.13K
- Avg vol
- 1.21M
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 94.68
- High
- 98.96
- Forward P/E
- -27.55
- Beta
- 3.11
- Short ratio
- 7.98
- Inst. own
- 108.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 90.28
- 200-d avg
- 72.91
- 1y target
- 122.33
2Y chart
Events in this range
- Aug 5, 2025Earnings: -0.49; estimate -0.73; surprise 32.88%
- Nov 4, 2025Earnings: -0.15; estimate -0.76076; surprise 80.28%
- Feb 19, 2026Earnings: -0.7; estimate -0.66; surprise -6.06%
- May 5, 2026Earnings: -0.74; estimate -0.66; surprise -12.12%
- Aug 4, 2026Earnings: -0.36; estimate -0.75885; surprise 52.56%
- Sep 8, 2026Rating: BTIG · Buy → Buy
- Sep 9, 2026Rating: Wedbush · Outperform → Outperform
- Oct 1, 2026Rating: BTIG · Buy → Buy
- Oct 1, 2026Rating: JP Morgan · — → Overweight
- Oct 12, 2026Rating: UBS · — → Buy
- Oct 19, 2026Rating: BTIG · Buy → Buy
Signals (84)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 8, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| RSI: Overbought | Apr 30, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 13, 2026 | 6 months ago |
| RSI: Overbought | Mar 31, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| RSI: Overbought | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 6, 2026 | 8 months ago |
| SMA: Bullish | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| RSI: Overbought | Dec 3, 2025 | 11 months ago |
| RSI: Overbought | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 4, 2025 | 12 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Oct 20, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| SMA: Bearish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 20, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| RSI: Overbought | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | May 22, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 17, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
Key statistics
- Market cap
- 9.02B
- Enterprise value
- 7.73B
- Trailing P/E
- 0.00
- Forward P/E
- -27.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.91
- EPS (TTM)
- -1.92
- Beta
- 3.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -89.05M
- Total cash
- 1.15B
- Total debt
- 0
- Return on equity
- -22.98%
- Shares outstanding
- 93.45M
- Short % of float
- 14.25%
- 50-day average
- 90.28
- 200-day average
- 72.91
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 122.33 +26.7% upside
Now 96.56
- Target (low)
- 110.00
- Target (mean)
- 122.33
- Target (high)
- 130.00
Ratings (0m) 18 17 buy · 1 hold · 0 sell
- Strong buy1
- Buy16
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.83521.
Financials — quick view
SYRE Revenue — quarterly 0
SYRE Net income — quarterly -36.20M
SYRE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.78502 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.75885 | -0.36 | +0.40 | +52.56% |
| May 5, 2026 | Mar 31, 2026 | -0.66 | -0.74 | -0.08 | -12.12% |
| Feb 19, 2026 | Dec 31, 2025 | -0.66 | -0.70 | -0.04 | -6.06% |
| Nov 4, 2025 | Sep 30, 2025 | -0.76076 | -0.15 | +0.61 | +80.28% |
| Aug 5, 2025 | Jun 30, 2025 | -0.73 | -0.49 | +0.24 | +32.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 1, 2026 | JP Morgan | init | — | Overweight |
| Oct 1, 2026 | BTIG | reit | Buy | Buy |
| Sep 9, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 8, 2026 | BTIG | reit | Buy | Buy |
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- spyre.com
News
Your note
Sign in to keep a note on SYRE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBERS JEFFREY W | Director | Sale | Aug 6, 2026 | 0 |
| BURROWS SCOTT L. | Chief Financial Officer | Sale | Sep 1, 2026 | 79,762 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unknown | Sale | Jun 22, 2026 | 0 |
| HENDERSON MICHAEL THOMAS | Director | Sale | Jun 21, 2026 | 68,606 |
| KING-JONES HEIDY | Officer | Sale | Sep 1, 2026 | 2,845 |
| SLOAN SHELDON | Officer | Sale | Jun 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.78% | 13,026,187 | 1.26B | Jun 29, 2026 |
| Blackrock Inc. | 6.38% | 6,506,605 | 628.28M | Jun 29, 2026 |
| Perceptive Advisors Llc | 4.24% | 4,319,496 | 417.09M | Jun 29, 2026 |
| RTW Investments LP | 4.17% | 4,251,996 | 410.57M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 3.77% | 3,840,778 | 370.87M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.38% | 3,448,681 | 333.00M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.71% | 2,760,132 | 266.52M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.44% | 2,482,298 | 239.69M | Jun 29, 2026 |
| SmallCap World Fund Inc | 2.21% | 2,247,758 | 217.04M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.95% | 1,982,310 | 191.41M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.67% | 1,699,846 | 164.14M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.88% | 896,559 | 86.57M | Jun 29, 2026 |